Rocket Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where holders of 80,774,659 common shares, representing approximately 74.02% of eligible shares, were present in person or by proxy. Stockholders elected seven directors, with support generally above 59 million votes for each nominee.
They ratified EisnerAmper LLP as independent registered accounting firm for the fiscal year ending December 31, 2026, with 79,195,009 votes for and 1,002,656 against. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers and approved a stock option exchange program as described in the 2026 Proxy Statement.
Form 144 notice reporting a proposed sale of 2,409 Common shares associated with a Restricted Stock Vesting event dated 05/15/2026. The filing also discloses 2,728 Common shares sold during the prior three months on 05/13/2026.
RCKT submitted a Rule 144 notice covering 662 shares of Common Stock.
The filing states the 662 shares arose from Restricted Stock Vesting dated 05/15/2026. It also records a separate sale of 3,361 shares on 05/13/2026 with proceeds of $12,118.42.
ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported an open-market sale of 3,361 shares of common stock at $3.606 per share. The footnotes state the shares were sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis. After this transaction, Wilson directly holds 678,639 shares, so the sale represents only a small portion of his overall position and appears tied to compensation-related taxes rather than a discretionary portfolio change.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small sale of common stock mainly tied to taxes on equity compensation. He sold 2,728 shares on May 13, 2026 at $3.606 per share to pay tax withholding obligations related to vesting restricted stock units.
After this sale, he directly holds 1,043,327 shares of common stock, with additional indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that these holdings include RSUs that convert one-for-one into common stock.
ROCKET PHARMACEUTICALS, INC. officer John Militello reported an open-market sale of common stock tied to equity compensation. He sold 855 shares at $3.606 per share, with the transaction occurring to cover tax withholding obligations from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.
After this sale, Militello directly holds 90,164 shares of common stock, including RSUs. The transaction represents a small portion of his overall reported holdings and is characterized in the footnotes as a tax-related disposition rather than a discretionary share sale.
RCKT submitted a Rule 144 notice disclosing 3,361 shares of Common Stock tied to a restricted stock vesting event dated 05/11/2026.
The filing also lists prior sales by Martin Wilson of 12,253 shares on 02/13/2026 for $40,583.16 and 1,376 shares on 02/18/2026 for $4,593.78.
Rocket Pharmaceuticals (RCKT) filed a Form 144 reporting proposed sales tied to recent restricted stock vesting. The filing lists 2,728 shares in a restricted stock vesting entry dated 05/11/2026 and two past reported dispositions by Gaurav Shah of 12,279 and 5,990 shares on 02/13/2026 and 02/18/2026, with associated dollar figures shown in the excerpt.
RCKT submitted a Form 144 reporting 855 shares of Common Stock to be sold in connection with Restricted Stock Vesting on 05/11/2026.
The filing also records prior sales: 3,726 shares on 02/13/2026 for $12,340.88 and 1,157 shares on 02/18/2026 for $3,862.64.
ROCKET PHARMACEUTALS, INC. insider Sarbani Chaudhuri reported an open-market sale of 17,650 shares of common stock at $3.838 per share on May 7, 2026. According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). After this transaction, Chaudhuri holds 267,510 shares of common stock, which includes RSUs that convert into common stock on a one-for-one basis.